Investigation Details
Zainab Mansaray-Storms, PhD , Evi Struble, PhD , Lu Deng, PhD , Nitin Verma , Hailing Yan, MS , Frantisek Bizik, PhD , Kavita Singh , Varsha Garnepudi , Emnet Yitbarek , Xiuju Lu , Pei Zhang, MD , Sairah Thommi, MD , Luisa Virata , Ngoc Ty Nguyen , Jianping Li, PhD , Yambasu Brewah, PhD , Anil Choudhary, PhD , Lisa Pham , Hongqiang Hu , Lilin Zhong, MS , Jie He , Jennifer Reed, PhD , Rana Nagarkatti , Julia Wright, MHA, RN , Triparna Poddar, PhD , Miranda Oakley , Jing Lin, PhD , Jennifer Chan, PharmD , Malgorzata Norton, MS , Parmesh Dutt , Virginie Dujols , Jun Lee, PharmD/PhD , Hahn Khuu , Ranadhir Dey , Xiaofei Wang, PhD , Erin Hill , Olga Simakova, PhD , Mathew Arnold , Parmesh Dutt, PhD , Nancy Eller, MHS , Jing Lin , Sarah Frasure, MD , Caren Chancey , Haecin Chun , Tao Pan , Krishna Mohan V Ketha , Emnet Yitbarek, PhD , Maria Virata, PhD , Claire Wernly, PhD , Brianna Davis , Afsah Amin, MD, MPH , Hyesuk Kong , Antonia Panthiruvelil , Kam Sang Kwok, PhD , Jun Lee
483s Issues in Countries
Form 483 Issued by Year
Top 5 Sub-Systems
Top 5 Co-Investigators
Investigator Analysis
George Kastanis is a detail-oriented FDA investigator who places a strong emphasis on GMP compliance and quality systems in drug substance and product manufacturing. He is particularly concerned about adherence to standard manufacturing protocols and the adequacy of quality control testing.
George Kastanis'' approach focuses on meticulously scrutinizing GMP compliance, quality systems, and manufacturing protocols. He prioritizes the identification of deficiencies and potential risks to product safety and efficacy during inspections.
Form 483s Issued
Get FDA Alerts on WhatsApp
Join Now for real-time alerts!





















.avif)






